Global Blood Therapeutics (NASDAQ:GBT) Rating Reiterated by Wedbush
Global Blood Therapeutics (NASDAQ:GBT) Rating Reiterated by Wedbush
Wedbush reiterated their neutral rating on shares of Global Blood Therapeutics (NASDAQ:GBT – Get Rating) in a research note issued to investors on Monday, Marketbeat reports. Wedbush also issued estimates for Global Blood Therapeutics' Q3 2022 earnings at ($1.35) EPS, Q4 2022 earnings at ($1.31) EPS, FY2022 earnings at ($5.17) EPS, Q1 2023 earnings at ($1.28) EPS, Q2 2023 earnings at ($1.31) EPS, Q3 2023 earnings at ($1.36) EPS, Q4 2023 earnings at ($0.67) EPS, FY2023 earnings at ($4.62) EPS, FY2024 earnings at ($1.44) EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at $3.41 EPS.
據Marketbeat報道,韋德布什在週一發佈給投資者的一份研究報告中重申了他們對全球血液治療公司(納斯達克:GBT-GET評級)股票的中性評級。韋德布什還發布了對全球血液治療公司2022年第三季度每股收益(1.35美元)、2022年第四季度每股收益(1.31美元)、2022年第四季度每股收益(5.17美元)、2023年第一季度每股收益(1.28美元)、2023年第二季度每股收益(1.31美元)、2023年第三季度每股收益(1.36美元)、2023年第四季度每股收益(0.67美元)、2023年第四季度每股收益(4.62美元)、2024財年每股收益(1.44美元)、2025財年每股收益(0.14美元)和2026財年每股收益3.41美元的預測。
A number of other research firms have also commented on GBT. JPMorgan Chase & Co. reduced their target price on Global Blood Therapeutics from $39.00 to $36.00 and set a neutral rating for the company in a report on Tuesday, June 28th. Canaccord Genuity Group raised Global Blood Therapeutics from a hold rating to a buy rating and lifted their target price for the stock from $40.00 to $72.00 in a report on Monday. StockNews.com raised Global Blood Therapeutics from a sell rating to a hold rating in a report on Thursday, May 5th. Canaccord Genuity Group raised Global Blood Therapeutics from a hold rating to a buy rating and lifted their target price for the stock from $40.00 to $72.00 in a report on Monday. Finally, William Blair lowered Global Blood Therapeutics from an outperform rating to a market perform rating in a report on Monday. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $65.04.
其他一些研究公司也對GBT發表了評論。摩根大通在6月28日週二的一份報告中將全球血液治療公司的目標價從39.00美元下調至36.00美元,併為該公司設定了中性評級。在週一的一份報告中,Canaccel Genuity Group將全球血液治療公司的評級從持有上調至買入,並將該股的目標價從40.00美元上調至72.00美元。在5月5日星期四的一份報告中,StockNews.com將全球血液治療公司的評級從賣出上調至持有評級。在週一的一份報告中,Canaccel Genuity Group將全球血液治療公司的評級從持有上調至買入,並將該股的目標價從40.00美元上調至72.00美元。最後,威廉·布萊爾在週一的一份報告中將全球血液治療公司的評級從表現優於市場下調至市場表現。10名投資分析師對該股的評級為持有,6名分析師對該股的評級為買入。根據MarketBeat.com的數據,該股的普遍評級為持有,平均目標價為65.04美元。
Global Blood Therapeutics Trading Down 0.4 %
全球血液治療公司股價下跌0.4%
GBT opened at $66.57 on Monday. Global Blood Therapeutics has a 52 week low of $21.65 and a 52 week high of $73.02. The company has a quick ratio of 7.74, a current ratio of 6.88 and a debt-to-equity ratio of 4.92. The stock has a market cap of $4.33 billion, a PE ratio of -13.29 and a beta of 0.83. The business has a 50 day moving average of $34.55 and a 200-day moving average of $31.84.
GBT週一開盤報66.57美元。全球血液治療公司的52周低點為21.65美元,52周高點為73.02美元。該公司的速動比率為7.74,流動比率為6.88,債務權益比率為4.92。該股市值為43.3億美元,市盈率為-13.29,貝塔係數為0.83。該業務的50日移動均線切入位在34.55美元,200日移動均線切入位在31.84美元。
Insider Transactions at Global Blood Therapeutics
全球血液治療公司的內幕交易
In other Global Blood Therapeutics news, Director Philip A. Pizzo sold 1,260 shares of the business's stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $27.25, for a total transaction of $34,335.00. Following the sale, the director now directly owns 9,112 shares of the company's stock, valued at $248,302. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.90% of the company's stock.
在其他全球血液治療公司的消息中,董事菲利普·A·皮佐在6月21日(星期二)的一筆交易中出售了1,260股該公司的股票。該股以27.25美元的平均價格出售,總成交金額為34,335.00美元。交易完成後,董事現在直接持有該公司9,112股股票,價值248,302美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份法律文件中披露的,該文件可通過以下超級鏈接獲得。內部人士持有該公司4.90%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds have recently modified their holdings of the business. Eubel Brady & Suttman Asset Management Inc. purchased a new stake in Global Blood Therapeutics during the first quarter worth $17,322,000. Deep Track Capital LP purchased a new stake in Global Blood Therapeutics during the fourth quarter worth $58,540,000. Goldman Sachs Group Inc. lifted its holdings in Global Blood Therapeutics by 48.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,833,720 shares of the company's stock worth $63,520,000 after buying an additional 595,983 shares during the period. Fairmount Funds Management LLC lifted its holdings in Global Blood Therapeutics by 59.1% during the first quarter. Fairmount Funds Management LLC now owns 1,182,307 shares of the company's stock worth $40,955,000 after buying an additional 439,307 shares during the period. Finally, Quinn Opportunity Partners LLC purchased a new stake in shares of Global Blood Therapeutics during the 1st quarter valued at $1,249,000.
多家對衝基金最近調整了對該業務的持股。Eubel Brady&Suttman資產管理公司在第一季度購買了全球血液治療公司價值17,322,000美元的新股份。Deep Track Capital LP在第四季度購買了全球血液治療公司價值58,540,000美元的新股份。高盛股份有限公司在第一季度增持了環球血液治療公司48.2%的股份。高盛股份有限公司在此期間增持了595,983股,目前持有1,833,720股該公司股票,價值63,520,000美元。Fairmount Funds Management LLC在第一季度增持了全球血液治療公司59.1%的股份。Fairmount Funds Management LLC現在擁有1,182,307股該公司的股票,價值40,955,000美元,在此期間又購買了439,307股。最後,Quinn Opportunity Partners LLC在第一季度購買了全球血液治療公司的新股份,價值1249,000美元。
Global Blood Therapeutics Company Profile
全球血液治療公司簡介
(Get Rating)
(獲取評級)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
全球血液治療公司是一家生物製藥公司,致力於發現、開發和提供針對服務不足的鐮狀細胞疾病(SCD)患者羣體的治療方法。該公司提供Oxbryta片劑,這是一種治療SCD的口服藥物,每天一次。它還在第二階段對青少年和兒童SCD患者的臨牀試驗中評估了單劑和多劑Oxbryta的安全性和藥代動力學。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 免費獲取StockNews.com關於全球血液治療(GBT)的研究報告
- 霍尼韋爾看好穩定和多元化的股票
- 為什麼要投資高收益股利股票?
- 找到並獲利於52周低點的股票交易
- 迪士尼(NYSE:DIS)的股票剛剛給了投資者一個巨大的信號
- 清潔能源法案通過後,太陽能股大放異彩
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《全球血液治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對全球血液治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。